Astra agrees £702m biotechnology deal

Pharmaceuticals giant AstraZeneca today announced it is to acquire one of the UK’s biggest biotechnology groups in a deal worth £702m (€1bn).

In a statement the firm said Cambridge Antibody Technology (CAT) will become central to AstraZeneca’s plans to “establish a major international presence in the research and development of biological therapeutics”.